Stroke Tech Funding Boost
RapidPulse Secures $48 Million Series B to Advance Next-Gen Stroke Aspiration Technology
Anonymous
RapidPulse has locked in a $48 million Series B round to push its stroke-clearing technology closer to US approval, according to The Province. The financing was oversubscribed — meaning investor demand exceeded the target — and was co-led by Medtronic, TechWald Next S.p.A., and S3 Ventures.
The money will fund the company's ongoing clinical trial and expand its patent portfolio. RapidPulse is developing a device that uses pulsed aspiration — a suction-based method — to remove blood clots from the brain during an acute ischemic stroke, Ottawa Sun reported.
What the RapidPulse System Actually Does
Acute ischemic stroke happens when a blood clot blocks an artery in the brain. Every second without blood flow damages brain tissue. RapidPulse's device aims to remove those clots faster and more completely than existing tools, according to The Sudbury Star.
The system uses pulsed aspiration — rapid bursts of suction — to break up and pull out clots. Traditional aspiration devices use steady suction. RapidPulse says the pulsing action may grab clots more effectively. The approach is designed to restore blood flow to the brain as quickly as possible, Woodstock Sentinel Review reported.
TURBO Trial Now Running in the US and Europe
RapidPulse is currently running a clinical trial called TURBO — short for Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions. The study is being conducted at sites in both the US and Europe, according to The Crag and Canyon.
The trial is an Investigational Device Exemption study — a type of US FDA-approved study that lets companies test unapproved medical devices on patients. Completing TURBO is the key step RapidPulse needs to seek full US regulatory clearance for the device, Seaforth Huron Expositor reported.
Medtronic Among Co-Leaders in Oversubscribed Round
The $48 million round was co-led by three investors: Medtronic, one of the world's largest medical device makers; TechWald Next S.p.A., a European life sciences investor; and S3 Ventures, a Texas-based venture fund, according to Ontario Farmer.
The fact that the round was oversubscribed signals strong investor confidence in RapidPulse's technology and market potential. Medtronic's involvement is notable — it is already a major player in the stroke treatment device market, making it both a financial backer and a potential strategic partner, The Province noted.
Where the $48 Million Will Go Next
RapidPulse plans to use the funds to complete the TURBO trial and expand its patent and proprietary technology platform. Growing its patent portfolio will help protect its pulsed aspiration technology from competitors, according to The Sudbury Star.
Stroke is a massive market. It is the leading cause of long-term disability in the US. Mechanical thrombectomy devices — tools that physically remove clots — represent a multi-billion-dollar global market. With $48 million now secured, RapidPulse has the runway to reach a regulatory decision, Woodstock Sentinel Review reported.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
7
Articles
6
Reach
7
A
AnonymousAuthor